Try our beta test site
14 studies found for:    Open Studies | "Respiratory Syncytial Virus Infections"
Show Display Options
Rank Status Study
1 Not yet recruiting Viral Inhibition in Children for Treatment of RSV
Condition: RESPIRATORY SYNCYTIAL VIRUS INFECTIONS
Interventions: Drug: AK0529;   Drug: Placebo
2 Recruiting A Study to Rank Different Dosages of Antigen of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A), Based on Their Immune Response and Safety, When Administered to Healthy Adult Women
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: RSV Vaccine (GSK3003891A) formulation 1;   Biological: RSV Vaccine (GSK3003891A) formulation 2;   Biological: RSV Vaccine (GSK3003891A) formulation 3;   Drug: Placebo (Formulation buffer S9b)
3 Recruiting A Study to Evaluate Safety and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine in RSV-seropositive Infants Aged 12 to 17 Months
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: RSV vaccine (GSK3389245A) low dose;   Biological: RSV vaccine (GSK3389245A) middle dose;   Biological: RSV vaccine (GSK3389245A) high dose;   Drug: Placebo LD;   Drug: Placebo MD;   Drug: Placebo HD
4 Recruiting A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Preterm Infants.
Condition: Respiratory Syncytial Virus Infections
Interventions: Drug: MEDI8897;   Drug: Placebo
5 Not yet recruiting RSV-MVA-BN Vaccine Phase I Trial, Intranasal Application in Adults.
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: MVA-BN-RSV;   Other: Placebo
6 Recruiting A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: RSV F vaccine with adjuvant;   Biological: Formulation buffer
7 Recruiting Safety and Immunogenicity of the RSV D46cpΔM2-2 Vaccine in RSV-Seropositive Children and RSV-Seronegative Infants and Children
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: D46cpΔM2-2 vaccine;   Biological: Placebo
8 Recruiting Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in Infants and Children
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: RSV ΔNS2 Δ1313 I1314L Vaccine;   Biological: Placebo (1x Leibovitz L-15 medium)
9 Recruiting A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Multiple Doses of Orally Administered JNJ-53718678 in Infants Hospitalized With Respiratory Syncytial Virus (RSV) Infection
Conditions: Respiratory Syncytial Virus Infections;   Virus Diseases
Interventions: Drug: JNJ-53718678;   Drug: Placebo
10 Recruiting A Study of Protective Immunity Against RSV and Influenza in Experimental Human Challenge of Volunteers
Conditions: Respiratory Syncytial Virus Infections;   Influenza, Human
Interventions: Biological: RSV A Memphis 37;   Biological: Influenza A/California/04/2009
11 Recruiting Utilization and Compliance of Respiratory Syncytial Virus Monoclonal Antibody Therapy
Conditions: Lower Respiratory Tract Infection;   Respiratory Syncytial Virus Infections
Intervention:
12 Recruiting Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus Infection of the Upper Respiratory Tract
Condition: Respiratory Syncytial Virus
Interventions: Drug: Presatovir;   Drug: Placebo
13 Recruiting Nasal and Bronchial Absorption Sampling in RSV Bronchiolitis
Conditions: Bronchiolitis;   Bronchiolitis, Viral;   RSV Infection;   Respiratory Failure
Intervention: Diagnostic Test: Nasal and Bronchial Sampling
14 Recruiting TGF-(Beta) and Susceptibility to RSV
Conditions: Respiratory Syncytial Virus;   Asthma
Intervention:

Study has passed its completion date and status has not been verified in more than two years.